2 Under-the-Radar Stocks to Buy Heading Into 2026
Axsome Therapeutics (NASDAQ: AXSM) and (NASDAQ: EXEL) are hardly the best-known players in the large biotech industry. Thankfully, they don't need to be so to have excellent prospects. Both of these relatively small drugmakers have a lot going on that could lead to excellent financial results and strong stock market performances in the medium term. Let's dig deeper into Axsome Therapeutics and Exelixis and discuss why both biotechs are attractive buys heading into the new year.
Image source: Getty Images.
Axsome Therapeutics has performed well over the past year as it continues to make strong clinical and regulatory progress while generating steadily growing revenue. The company's Auvelity, approved for major depressive disorder in 2022, is making headway. It is currently its main growth driver. In the third quarter, Axsome Therapeutics' revenue increased by 63% year over year to $171 million.
Source Fool.com
Axsome Therapeutics Inc Aktie
Die Axsome Therapeutics Inc Aktie hat nicht genug Feedback für eine deutliche Meinung.
Das Community-Kursziel von 75 € für Axsome Therapeutics Inc deutet auf eine deutliche Minderung um mehr als 20% gegenüber dem aktuellen Kurs von 126.25 € hin.
